Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6612.0000 -19.50 (-0.29%)
NSE May 30, 2025 15:31 PM
Volume: 786.6K
 

6612.00
-0.29%
ICICI Securities Limited
Divi’s Laboratories’ (Divi’s) has posted its highest ever quarterly sales in generics segment of Rs10bn, up 42% YoY in Q4FY23, though a surge in raw material price and overhead cost has impacted margins (down 1,670bps YoY). Management has indicated a gradual improvement in margins Q1FY24 onwards as it has exhausted high-priced inventory and raw material prices are also declining.
Divi's Laboratories Ltd. has gained 49.84% in the last 1 Year
More from Divi's Laboratori…
All earning calls
Investor presentations from Divi's Laboratori…
All investor presentations